EANM 2022 Congress
At EANM this year, we will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in neuroendocrine and other radiosensitive tumors and prostate cancer, showcasing the impact of our bold science in cancer research.
Bold Science: Transforming Lives, Striving for Cures
Reimagining Cancer and Blood Disorders
Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients’ hopes for the future. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines.
Advanced Accelerator Applications (AAA), a Novartis Company, is an innovative medicines company focused on the development of products for targeted radioligand therapy and precision radioligand imaging.